Semafore Pharmaceuticals Announces Presentation Highlighting Activity of Multi-Kinase, PI3K/mTOR Inhibitor SF1126 at 2011 AACR Annual Meeting
March 09, 2011 07:30 ET
|
Semafore Pharmaceuticals
INDIANAPOLIS, March 9, 2011 (GLOBE NEWSWIRE) -- Semafore Pharmaceuticals announced today that preclinical data in B-cell malignancies for the company's lead product candidate SF1126 will be presented...